Company / R&D Expense
Akebia Therapeutics, Inc. R&D Expense History
FY2014-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$62.4M
FY2025
5-year range
$37.7M / $323.0M
FY2021-FY2025
Trend
+65.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense returned to growth in FY2025 after 3 years of decline, reaching $62M.
Based on SEC 10-K filings.
$62M in FY2025 with a 10-year CAGR of +21.5%.
Remained stable around $62M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -21.7%
- 5-Year CAGR
- -26.5%
- 10-Year CAGR
- +21.5%
Key checks
Key Insights
- 5-year CAGR of -26.5%, indicating a declining trend.
- In FY2025, r&d expense increased 65.6% year-over-year.
- Peak r&d expense was recorded in FY2021.
- Lowest r&d expense in the period was in FY2014.
Company context
Key Data Points
- Altman Z-Score -2.76 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $62.4M | +65.6% |
| FY2024 | $37.7M | -40.3% |
| FY2023 | $63.1M | -51.5% |
| FY2022 | $130.0M | -59.8% |
| FY2021 | $323.0M | +11.0% |
| FY2020 | $291.0M | +26.0% |
| FY2019 | $230.9M | +99.4% |
| FY2018 | $115.8M | +1200.7% |
| FY2015 | $8.9M | +58.1% |
| FY2014 | $5.6M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026